EverHint Lens - Moderna, Inc. (MRNA) - Yahoo Finance Top Gainer Stock Analysis - August 19, 2026

Analysis Date: 2026-08-19
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Moderna, Inc. is currently trading at $143.81 (🟢 +128.41% today) with a market capitalization of $57.06B.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.

Price & Valuation

Current Price: $143.81 (at 12:02 PM ET)
Current Volume: 113.3M
Day Range: $114.46 - $163.47
52-Week Range: $22.28 - $163.47
P/E Ratio: -17.71

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-08-18.

Market Context

Major Indices:

• S&P 500: $7730.18 (🟢 +0.50%)
• NASDAQ Composite: $26417.96 (🟢 +0.49%)
• Dow Jones Industrial Average: $53512.12 (🟢 +0.32%)

Peer Comparison

Peer comparison (11 companies):

• MRNA - Moderna, Inc. ($143.81, +128.4%, $57.06B) ← Current
• RVMD - Revolution Medicines, Inc. ($213.46, -1.2%, $45.38B)
• BBIO - BridgeBio Pharma, Inc. ($83.62, +0.8%, $16.38B)
• JAZZ - Jazz Pharmaceuticals plc ($253.33, +0.1%, $15.91B)
• EXEL - Exelixis, Inc. ($54.07, +1.8%, $13.59B)
• BMRN - BioMarin Pharmaceutical Inc. ($68.70, +2.6%, $13.28B)
• HALO - Halozyme Therapeutics, Inc. ($106.16, +1.2%, $12.59B)
• MDGL - Madrigal Pharmaceuticals, Inc. ($534.56, +1.9%, $12.35B)
• TECH - Bio-Techne Corporation ($72.48, +0.4%, $11.35B)
• CAI - Caris Life Sciences, Inc. ($22.91, +9.3%, $6.48B)
• RNA - Atrium Therapeutics, Inc. ($13.40, +4.4%, $229M)

Financial Performance

Latest Quarter (2026-06-30):

• Revenue: $145.00M
• Net Income: $-782.00M
• EPS: $-1.96
• Revenue Growth (QoQ): -62.7%

Earnings Calendar

Next Earnings Report: 2026-11-05 (Before Market Open)

• EPS Estimate: $-1.38
• Revenue Estimate: $0.87B

Most Recent Report: 2026-07-31

• EPS: $-1.97 (Est: $-2.03) ✓ Beat
• Revenue: $0.14B

Historical Data: 39 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $79.44 (-44.8% upside)
• Range: $25.00 - $245.00
• Median: $45.00

Next Quarter Estimates (2027-12-30):

• Revenue: $985.65M
• EPS: $-0.94

Analyst Consensus

Overall Rating: Buy

Rating Distribution (199 total ratings):

• 🟢 Buy/Outperform: 79 (39.7%)
• ⚪ Hold/Neutral: 47 (23.6%)
• 🔴 Sell/Underperform: 26 (13.1%)

Recent Analyst Actions:

• William Blair (2026-08-19): Upgrade Underperform → Outperform
• William Blair (2026-05-08): Downgrade Market Perform → Underperform
• Wells Fargo (2026-05-08): Upgrade Equal-Weight → Outperform
• BMO Capital (2026-01-12): Upgrade Market Perform → Buy
• UBS (2026-01-06): Downgrade Buy → Neutral

Consensus based on 199 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 3 trading signal(s) in the last 60 days:

• 2026-08-13: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $63.65
• 2026-08-07: Sma20 Sma50 - SMA20_x_SMA50_Sell @ $59.17
• 2026-07-06: Momentum Swing - breakout @ $81.80

Insider Activity

Recent Transactions (Last 10):

• Buys: 3
• Sells: 7

Notable Transactions:

• 2026-08-05: Bancel Stephane - Buy (Option Exercise, 499,246 shares @ $19.15)
• 2026-08-05: Bancel Stephane - Sell (Sale, 147,473 shares @ $56.21)
• 2026-08-06: Bancel Stephane - Buy (Option Exercise, 252,469 shares @ $19.15)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

House of Representatives: 49 transactions tracked

Recent Activity:

• 🔴 Ro Khanna (CA17): Sale on 2026-01-29 @ $46.86, Amount: $1,001 - $15,000
• 🔴 Ro Khanna (CA17): Sale on 2025-08-26 @ $24.73, Amount: $1,001 - $15,000
• 🟢 Ro Khanna (CA17): Purchase on 2025-07-25 @ $34.15, Amount: $1,001 - $15,000
• ⚪ Rob Bresnahan (PA08): Sale (Full) on 2025-04-08, Amount: $1,001 - $15,000
• 🟢 Rob Bresnahan (PA08): Purchase on 2025-02-25, Amount: $1,001 - $15,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent news is dominated by positive Phase 3 trial results for Moderna's personalized mRNA cancer vaccine with Merck for melanoma, triggering a massive stock surge exceeding 100% and record losses for short-sellers. This breakthrough validates mRNA technology beyond COVID and overshadows earlier coverage of flu vaccine approval and cost-cutting efforts.

Key Themes:

• Cancer Vaccine Breakthrough
• Stock Surge on Trial Data
• Merck Collaboration Success

Sentiment: Positive (90% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Slightly Bullish 📈 (Score: 0.268)

Post Analysis:

• Total posts: 12
• Bullish: 5 (41.7%)
• Bearish: 4 (33.3%)
• Neutral: 3 (25.0%)
• Total engagement: 4,292 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering MRNA:

• Earnings, Cancer Vaccine, Long-Term Liquidity: A Busy Pre-Market (zacks.com, 2026-08-19) — Read more
• Moderna short-sellers stare at record one-day loss as shares surge on vaccine data (reuters.com, 2026-08-19) — Read more
• Moderna's Cancer Vaccine Win Is Merck's Story Too (benzinga.com, 2026-08-19) — Read more
• Moderna Co-Founder Robert Langer Is A Billionaire Again As Shares Double In Value (forbes.com, 2026-08-19) — Read more
• S&P500: Treasury Buyback Lifts US Stocks as Moderna Cancer Data Sparks Rally (fxempire.com, 2026-08-19) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis r/Everhint
Last updated: 2026-08-19 09:02:58 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.